Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
- Conditions
- Metastatic Melanoma
- Registration Number
- NCT00226473
- Lead Sponsor
- Dermatologic Cooperative Oncology Group
- Brief Summary
- The purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy according to the CVD- scheme. So far neither established treatment regimes nor reliable data exist for the second-line chemotherapy of metastatic malignant melanoma. Patients are therefore mostly treated with single or multiple chemotherapeutics or/and immunomodulatory therapeutics. These regimes however imply often not only a higher toxicity but show rarely a response rate higher than 10%. 
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
- histological diagnosis of metastatic melanoma (stage IV)
- progressive disease after first-line chemotherapy or immuno-chemotherapy
- Karnofsky-index > 60%
- informed consent
- Uvea melanoma
- another primary malignancy except basal cell carcinoma or cervical carcinoma in situ
- severe and/or uncontrolled medical disease (diabetes mellitus, cardiac insufficiency)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
- Name - Time - Method - Overall survival 
- Secondary Outcome Measures
- Name - Time - Method - Quality of life analysis - Objective tumor response rate in study arm B - Time to tumor progression - Cost analysis 
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (13)
- Skin Cancer Unit, German Cancer Ressearch Center and Dept. of Dermatology, University Hospital of Mannheim 🇩🇪- Mannheim, Baden-Württemberg, Germany - Dept. of Dermatology, University Hospital Tuebingen 🇩🇪- Tuebingen, Baden-Württemberg, Germany - Dept. of Dermatology, University of Frankfurt 🇩🇪- Frankfurt, Hessen, Germany - Dept. of Dermatology, Medical Center Buxtehude 🇩🇪- Buxtehude, Niedersachsen, Germany - Dept. of Dermatology, Hildesheim 🇩🇪- Hildesheim, Niedersachsen, Germany - Dept. of. Dermatology, University of Saarland, Homburg 🇩🇪- Homburg, Saaland, Germany - Dept. of Dermatology, University Otto von Guericke 🇩🇪- Magdeburg, Saxony-Anhalt, Germany - Dept. of Dermatology, University of Schleswig-Holstein 🇩🇪- Kiel, Schleswig-Holstein, Germany - Dept. of Dermatology, University of Schleswig-Holstein, Campus Lübeck 🇩🇪- Lübeck, Schleswig-Holstein, Germany - Dept. of Dermatology, Helios Clinic Erfurt 🇩🇪- Erfurt, Thuringia, Germany Scroll for more (3 remaining)Skin Cancer Unit, German Cancer Ressearch Center and Dept. of Dermatology, University Hospital of Mannheim🇩🇪Mannheim, Baden-Württemberg, GermanyDirk Schadendorf, MDPrincipal Investigator
